A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1474-1480

  Wang, Xianhuo ^a   Zhou, Junchao ^a   Wang, Yongsheng ^a   Zhu, Zhengyan ^a   Lu, You ^a   Wei, Yuqan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Clinical efficacy; Intrapleural injection; Liposome; Malignant pleural effusions; Non small cell lung cancer; Paclitaxel; Pharmacokinetics; Phase I; Toxicity; Treatment

Indexed keywords

LIPOSOME; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; FEASIBILITY STUDY; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROTOXICITY; NEUTROPENIA; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; URINALYSIS; COMPLICATION; DOSE RESPONSE; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PLEURAL EFFUSION, MALIGNANT; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PLEURAL EFFUSION, MALIGNANT; TREATMENT OUTCOME;

EID: 77951880109     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.002     Document Type: Article

References (16)

1. Fenton K.N., and Richardson J.D. Diagnosis and management of malignant pleural effusions. Am J Surg 170 1 (1995) 69-74
2. Antony V.B., Loddenkemper R., Astoul P., et al. Management of malignant pleural effusions. Eur Respir J 18 2 (2001) 402-419
3. Reeder L.B. Malignant pleural effusions. Curr Treat Options Oncol 2 (2001) 93-96
4. Livingston R.B., McCracken J.D., Trauth C.J., and Chen T. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. Chest 81 2 (1982) 208-211
5. Marchi E., Teixeira L.R., and Vargas F.S. Management of malignancy-associated pleural effusion: current and future treatment strategies. Am J Respir Med 2 3 (2003) 261-273
6. Walker-Renard P.B., Vaughan L.M., and Sahn S.A. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 120 1 (1994) 56-64
7. Rusch V.W., Figlin R., Godwin D., and Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9 2 (1991) 313-319
8. Perng R.P., Chen Y.M., Wu M.F., et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med 92 3 (1998) 473-479
9. Perng R.P., Wu M.F., Lin S.Y., Chen Y.M., Lin J.Y., and Whang Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anti-Cancer Drugs 8 6 (1997) 565-573
10. Gilbar P., and Ridge A. Dexamethasone prophylaxis for paclitaxel hypersensitivity. J Oncol Pharm Pract 8 (2002) 81-87
11. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 6 (1982) 649-655
12. Markman M., Rowinsky E., Hakes T., et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol 10 9 (1992) 1485-1491
13. Murphy W.K., Fossella F.V., Winn R.J., et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85 5 (1993) 384-388
14. Chang A.Y., Kim K., Glick J., Anderson T., Karp D., and Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85 5 (1993) 388-394
15. Szebeni J., Muggia F.M., and Alving C.R. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90 4 (1998) 300-306
16. Drummond D.C., Meyer O., Hong K.L., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51 4 (1999) 691-743